Survodutide vs Tirzepatide
Extensively Studied vs FDA Approved
avoid Mechanism-based · 70% Both Survodutide and Tirzepatide activate GLP-1 receptors. Combining GLP-1 agonists significantly increases risk of severe GI side effects (nausea, vomiting, pancreatitis). Not recommended.
Molecular Data
Survodutide Tirzepatide
Weight ~4,500 Da 4,813.55 Da
Half-life Approximately 6 days (109-115 hours) ~5 days (120 hours)
Chain 29 amino acids 39 amino acids
Type Peptide with fatty acid acylation Dual GLP-1/GIP agonist
Key Benefits
Survodutide
01 Superior weight loss vs monotherapy (14.9% at 46 weeks)
02 Once-weekly convenient dosing
03 Proven efficacy in obesity, MASH, and Type 2 diabetes
04 62% MASH improvement in clinical trials
Tirzepatide
01 Dramatic weight loss (15-22% body weight)
02 Superior diabetes control
03 Reduced cardiovascular risk (26% reduction in MACE)
04 Improved insulin sensitivity
05 Appetite suppression
06 Preserved muscle mass with exercise
Dosing Protocols
Survodutide
0.6mg starting, titrate up to 3.6-6.0mg weekly / Once weekly (same day each week)
Obesity - Conservative Start 0.6mg titrated over 24 weeks Once weekly with 4-week intervals
Obesity - Standard Protocol 3.6-6.0mg Once weekly
MASH Treatment 2.4-4.8mg Once weekly
Type 2 Diabetes 0.3-2.7mg Once weekly
Tirzepatide
2.5mg starting, titrate up to 5-15mg weekly / Once weekly (same day each week)
Weight loss initiation 2.5mg Once weekly x 4 weeks
Weight loss progression 5mg Once weekly
Weight loss optimization 7.5-10mg Once weekly
Maximum weight loss 12.5-15mg Once weekly
Diabetes management (mild) 5-7.5mg Once weekly
Diabetes management (severe) 10-15mg Once weekly
Side Effects
Survodutide
Nausea (40-66%)
Diarrhea (25-49%)
Vomiting (15-41%)
Slight heart rate increase (mean 2-5 bpm)
Tirzepatide
Nausea (mild to moderate, first 2-4 weeks)
Appetite reduction
Possible fatigue during adaptation
Diarrhea or constipation
Reduced food cravings
Contraindications
Not recommended in pregnancy or breastfeeding
Use contraception during treatment
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
Survodutide Tirzepatide
Status Extensively Studied FDA Approved
References 3 studies 8 studies
Latest — 2025-12
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.